Core Viewpoint - Royal Philips has announced the acquisition of SpectraWAVE, Inc., which specializes in Enhanced Vascular Imaging (EVI) and AI applications in medical imaging, aimed at improving treatment for coronary artery disease, a condition affecting over 300 million people globally [2][4][6]. Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation [15][16]. - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people [16]. Acquisition Details - The acquisition of SpectraWAVE will enhance Philips' portfolio in the coronary intervention segment, integrating AI-powered innovations in intravascular imaging and physiological assessment [4][7][9]. - Financial terms of the acquisition have not been disclosed [13]. Technology Integration - SpectraWAVE's HyperVue Imaging System combines DeepOCT and NIRS technologies to provide detailed imaging of coronary arteries during procedures, facilitating rapid setup and automated AI analysis [8][10]. - The X1-FFR technology from SpectraWAVE offers AI-enabled physiological assessments from a single angiogram, enhancing the workflow for percutaneous coronary interventions [11]. Market Impact - The integration of SpectraWAVE's technologies with Philips' Azurion platform is expected to significantly increase the adoption of advanced imaging and physiological assessment in treating coronary artery disease [9][12]. - Philips aims to expand clinician choice and improve patient outcomes through the convergence of intravascular imaging, coronary physiology, and AI [6][7].

Core Insights - Royal Philips has announced an agreement to acquire SpectraWAVE, Inc., which specializes in Enhanced Vascular Imaging (EVI) and AI applications in medical imaging, particularly for coronary artery disease [5][10][14] - The acquisition aims to enhance Philips' capabilities in image-guided therapy, particularly in the coronary intervention segment, by integrating SpectraWAVE's advanced technologies [7][10][14] Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation, with a strong emphasis on image-guided therapy [19] - SpectraWAVE, founded in 2017 and based in Bedford, Massachusetts, employs over 70 people and is recognized for its innovative intravascular imaging and physiological assessment technologies [5][19] Technology and Product Integration - The acquisition will incorporate SpectraWAVE's HyperVue Imaging System, which combines DeepOCT and NIRS technologies for detailed imaging of coronary arteries during procedures [11][14] - SpectraWAVE's X1-FFR technology provides AI-enabled physiological assessments from a single angiogram, enhancing the workflow for percutaneous coronary interventions [12][14] Market Impact - The integration of SpectraWAVE's technologies is expected to significantly increase the adoption of coronary intravascular imaging and physiological assessment, improving patient outcomes [10][14] - Philips' Azurion platform, which is already used to treat over 7.6 million patients annually in more than 80 countries, will benefit from the addition of SpectraWAVE's innovations [15][19]

Philips LumiGuide 3D device guidance in use Philips LumiGuide 3D device guidance in use December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands an ...

Core Viewpoint - Royal Philips has announced the expanded commercial availability of LumiGuide 3D Device Guidance, the first real-time AI-enabled light-based 3D navigation solution for image-guided therapy, across Europe and the United States, marking a significant advancement in radiation-free navigation technology [2][10]. Group 1: Product Overview - LumiGuide allows physicians to visualize and guide devices inside the body using light instead of continuous X-ray, enhancing radiation safety and dose reduction in image-guided therapy [2][5]. - The technology integrates seamlessly with Philips' Azurion platform, which is designed to drive procedural innovation across various clinical domains [3][9]. - LumiGuide utilizes Fiber Optic RealShape (FORS) technology to provide high-resolution, full-color images in real-time, enabling precise navigation during complex endovascular procedures [5][8]. Group 2: Clinical Impact - Clinical experiences indicate that LumiGuide can improve efficiency, reduce procedure time, and minimize fluoroscopy pedal usage, with complex aortic repair procedures performed 37% faster and with up to 56% reduction in dose area product (DAP) [4][5]. - Over 2,000 clinical procedures have utilized LumiGuide, demonstrating its effectiveness and integration with the Azurion platform [10]. Group 3: Market Expansion - Following a successful limited market release in late 2023, LumiGuide will be commercially available from January 2026 in key European markets and the United States, expanding access to advanced image-guided therapy [10][14]. - Philips aims to enhance the adoption of this technology in hospitals to improve treatment precision and safety while reducing radiation risks for both patients and clinical staff [6][7]. Group 4: Commitment to Safety - LumiGuide is part of Philips' broader portfolio aimed at reducing or eliminating radiation exposure during image-guided procedures, reinforcing the company's leadership in low- and no-dose interventional solutions [11][14]. - The integration of LumiGuide with other technologies like Azurion with ClarityIQ and DoseAware further emphasizes Philips' commitment to advancing radiation safety in medical procedures [11].

Q2 2025 Performance Highlights - Order intake increased by 6% year-on-year, and the order book increased by 7% year-on-year[11] - Sales grew by 1%, driven by growth in Personal Health, but partially offset by performance in Diagnosis & Treatment and Connected Care[11] - Adjusted EBITA margin increased by 130 bps to 12.4%[11] - Free cash flow increased from slightly positive to EUR 0.2 billion-0.4 billion, net of Respironics settlement[11] Order Book and Regional Performance - The order book is up 7% year-on-year, with an improved margin profile driven by recently launched innovations[16] - The order book accounts for approximately 40% of revenue[16] Financial Performance by Segment - Diagnosis & Treatment sales decreased by 1%[26] - Connected Care sales decreased by 1%[30] - Personal Health sales grew by 6%[38] Productivity and Outlook - Productivity initiatives delivered EUR 344 million year-to-date and are on track to deliver EUR 800 million in 2025[46] - The adjusted EBITA margin range is increased by 50 bps to 11.3%-11.8%[11]

Core Insights - Royal Philips has announced the CE-marking of its SmartCT image reconstruction solution, enhancing decision-making in stroke and neurovascular treatment [1][3] - SmartCT is designed for the Philips Azurion neuro biplane system, providing real-time 3D imaging directly in the Angio suite, which accelerates treatment and improves clarity [2][9] - The technology is already in use at leading stroke centers globally, streamlining workflows and supporting timely interventions, particularly in mechanical thrombectomy procedures [3][4] Product Features - SmartCT 3.0 delivers cone-beam CT imaging in as little as 8 seconds, optimizing image quality for cerebral soft tissue and aiding in the visualization of vessel occlusions [9] - The system includes motion-compensated imaging for restless patients and features like SmartCT Dual Viewer for real-time image fusion and enhanced procedural planning [9] - Philips will showcase SmartCT 3.0 at LINNC Paris 2025, highlighting its capabilities for neuro-endovascular treatments [6] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, with 2024 sales of EUR 18 billion and operations in over 100 countries [10][11] - The company specializes in diagnostic imaging, ultrasound, image-guided therapy, and personal health solutions, employing approximately 67,200 people [11]